Cat. No. 3236
Biological ActivityPotent and competitive pituitary adenylate cyclase-activating polypeptide receptor (PAC)1 antagonist (IC50 = 2 nM). Inhibits PACAP(1-27)-induced stimulation of adenylate cyclase (Ki = 1.5 nM). Antitumor activity in vivo.
(Modifications: Lys-33 = C-terminal amide)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Robberecht et al (1992) Structural requirements for the occupancy of pituitary adenylate-cyclase-activating-peptide (PACAP) receptors and adenylate cyclase activation in human neuroblastoma NB-OK-1 cell membranes. Discovery of PACAP(6-38) as a potent antagonist. Eur.J.Biochem. 207 239. PMID: 1321043.
Leyton et al (1998) PACAP(6-38) inhibits growth of prostate cancer cells. Cancer Lett. 125 131. PMID: 9566707.
Kojro et al (2006) The neuropeptide PACAP promotes a-secretase pathway for processing Alzheimer amyloid precursor protein. FASEB J. 20 512. PMID: 16401644.
If you know of a relevant citation for this product please let us know.
Keywords: PACAP 6-38, supplier, Potent, PAC1, receptors, antagonists, Pituitary, Adenylate, Cyclase, Activating, Peptide, PACAP638
Find multiple products by catalog number
New Products in this Area
Endogenous reported anorexigenic peptideTC NTR1 17
Selective non-peptide NTS1 agonistML 354
Selective PAR4 antagonistGW 438014A
NPY Y5 receptor antagonistTC-FPR 43
Potent FPR2 agonistTC-G 1003
High affinity somatostatin sst2 receptor agonistKisspeptin 10 (dog)
Endogenous ligand for canine kisspeptin receptor
July 4 - 9, 2015